CardioGenics Holdings Inc. (OTCBB: CGNH) announced today that it has retained The Equicom Group Inc. (Equicom) to provide investor relations services in North America. “CardioGenics is working tirelessly to advance commercialization efforts of its products and is also moving rapidly to test its QL Care Platform as it anticipates a potential future FDA approval,” said Dr. Yahia Gawad, CEO of CardioGenics. “Equicom, a leading IR firm in the healthcare and life sciences space, positions us to enhance our communications around these advancements, increase our profile and broaden our awareness amongst the financial community.”
